Lyell Immunopharma (LYEL) stock dropped on Friday despite incredibly positive coverage from a top Wall Street analyst. Four-star Needham analyst Gil Blum initiated coverage of Lyell Immunopharma with a Buy rating and a $44 price target, suggesting a possible 92.73% upside for the shares. Investors will note that Blum’s LYEL price target is just shy of the Street-high price target of $45 set by four-star H.C. Wainwright analyst Mitchell Kapoor late last month.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Blum’s bullish stance on Lyell Immunopharma is due to a variety of positive factors. Among these are the company’s dual CD19/CD20 CAR-T for aggressive Diffuse Large B-Cell Lymphoma, which appears to have better performance and a more stable safety profile than the current standard of care. The analyst also highlighted positive progress on LYL273, a CAR-T candidate for metastatic colorectal cancer.
Finally, Blum pointed out Lyell Immunopharma’s cash reserves. The company’s $297 million should allow it to continue operations in the second quarter of 2027. This gives it runway to produce more results from its pipeline of medical treatments.
Lyell Immunopharma Stock Movement Today
Lyell Immunopharma stock was down 3.69% on Friday, extending a 25.37% year-to-date drop. Despite this, the stock was still up 171.98% over the past 12 months.
LYEL stock trading activity today saw some 32,000 shares change hands, compared to a three-month average daily trading volume of about 93,000 shares.
Is Lyell Immunopharma Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Lyell Immunopharma is Strong Buy, based on three Buy ratings over the past three months. With that comes an average LYEL stock price target of $41, representing a potential 78.49% upside for the shares.
